DC
CGON icon

Decheng Capital’s CG Oncology CGON Stock Holding History

Decheng Capital’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453M Hold
6,371,669
– – 61.87% 1
2026
Q1 		$431M Hold
6,371,669
– – 65.21% 1
2025
Q4 		$265M Hold
6,371,669
– – 35.59% 1
2025
Q3 		$257M Hold
6,371,669
– – 44.78% 1
2025
Q2 		$166M Hold
6,371,669
– – 41.84% 1
2025
Q1 		$156M Hold
6,371,669
– – 43.77% 1
2024
Q4 		$183M Buy
6,371,669
+892,859
+16% +$30.5M 39.2% 1
2024
Q3 		$207M Buy
5,478,810
+20,000
+0.4% +$701K 48.96% 1
2024
Q2 		$172M Hold
5,458,810
– – 52.81% 1
2024
Q1 		$240M Buy
+5,458,810
New +$223M 32.14% 2

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Decheng Capital's CGON Position: Q2 2026 in Review

Decheng Capital held its CG Oncology (CGON) position steady in Q2 2026 at 6,371,669 shares worth $453M. The position accounts for 61.87% of the portfolio, ranked #1.

Decheng Capital first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Decheng Capital held 6,371,669 shares of CG Oncology worth $453M as of Q2 2026.
  • Decheng Capital left its CG Oncology share count unchanged in Q2 2026.
  • CG Oncology made up 61.87% of Decheng Capital's portfolio in Q2 2026, its #1 holding.
  • Decheng Capital first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.